Characterization of the Population with BRAF V600 Mutation in Patients with Metastatic Cutaneous Melanoma in a Tertiary Center
Abstract
Introduction: Although corresponding to only 5% of cutaneous neoplasms, melanoma is the tumor of this organ with the highest mortality rate. The constant development of new drugs, particularly those targeting the B-Raf protein, has significantly increased overall patient survival. To date, several studies have evaluated the clinical-pathological correlations with this mutation. However, no study has been published regarding the Portuguese population.
Material & Methods: In the present study, the authors investigated the existence of clinico-pathological correlations with the presence or absence of BRAF mutation in a population of patients with metastatic cutaneous melanoma, in order to identify prognostic factors related to this cell signaling pathway.
Results: A total of 197 melanoma patients’ clinical processes with BRAF mutation tested, observed at the IPOLFG Dermatology Service between January 2012 and December 2016, were evaluated. The BRAF mutation was documented in 46.7% (n=92) of the patients, 60% of which (n=56) were male. Fifty-two percent (n=48) of the primary tumors were located in the trunk, suggesting the association of the mutation with intermittent sun exposure. In 40% of patients (n=79) metastasis occurred at multiple anatomical sites. The percentage of patients with metastasis in a single anatomical site was 60% (n = 118), with the most frequently involved sites being locoregional ganglion chains (36%, n=43) and lung (26.6%, n=25).
Conclusion: The results presented did not reveal differences in the studied Portuguese population, in agreement with those documented for other populations and described in the literature.
Downloads
References
Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355:51-65.
Schadendorf D, van Akkooi AC, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392:971-84. doi: 10.1016/S0140-6736(18)31559-9.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16. doi: 10.1056/NEJMoa1103782.
Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-51.
Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-66.
Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118-25.
Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738-45.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma.
N Engl J Med. 2005;353:2135-47.
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity.
;48:812-830.e14. doi: 10.1016/j.immuni.2019.08.004.
Hacker E, Hayward NK, Dumenil T, James MR, Whiteman DC. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: Findings from an Australian population. J Invest Dermatol. 2010;130:241-8. doi: 10.1038/jid.2009.182.
Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, Goetz R, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004;3:6. doi: 10.1186/1477-3163-3-6.
Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, et al. Distinct clinical and pathological features are associated
with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol. 2006;127:900-5.
Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, et al. Improving melanoma classification by integrating
genetic and morphologic features. PLoS Med. 2008;5:e120. doi: 10.1371/journal.pmed.0050120.
Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev. 2007;16:991-7.
Chang DZ, Panageas KS, Osman I, Polsky D, Busam K, Chapman PB. Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med. 2004;2:e46.
Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 2003;63:3955-7.
Gallagher SJ, Thompson JF, Indsto J, Scurr LL, Lett M, Gao BF, et al. P16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. Neoplasia. 2008;10:1231-9.
Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S, et al. BRAF mutations in metastatic melanoma: A possible association with clinical outcome. Clin Cancer Res. 2003;9:3362-8.
Sosman JA, Kim KB, Schuchter L. Survival in BRAFV600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-14.
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, openlabel, phase 3 randomised controlled trial. Lancet. 2012;380:358-65. doi: 10.1016/S0140-6736(12)60868-X.
Schadendorf D, Livingstone E, Zimmer L. Treatment in metastatic melanoma-time to re-think. Ann Oncol. 2019;30:501-3. doi: 10.1093/annonc/mdz050.
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib
in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813-23. doi: 10.1056/NEJMoa1708539.
McKean MA, Amaria RN. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant
and neoadjuvant therapy. Cancer Treat Rev. 2018;70:144-53. doi: 10.1016/j.ctrv.2018.08.011.
Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage iii melanoma. J Clin Oncol. 2018:JCO1801219. doi: 10.1200/JCO.18.01219
Kwak M, Farrow NE, Salama AK, Mosca PJ, Hanks BA, Slingluff CL,et al. Updates in adjuvant systemic therapy for melanoma. J Surg Oncol. 2019;119:222-31. doi: 10.1002/jso.25298.
Liu JY, Lowe M. Neoadjuvant treatments for advanced resectable melanoma. J Surg Oncol. 2019;119:216-21. doi: 10.1002/jso.25352.
Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, et al. Adjuvant vemurafenib in resected,
BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19:510-20. doi: 10.1016/S1470-2045(18)30106-2.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:603-15. doi: 10.1016/S1470-2045(18)30142-6.
Saroufim M, Habib R, Karram S, Youssef Massad C, Taraif S, Loya A, et al. BRAF analysis on a spectrum of melanocytic
neoplasms: an epidemiological study across differing UV regions. Am J Dermatopathol. 2014;36:68-73. doi: 10.1097/DAD.0b013e318293f355.
Kim SY, Kim SN, Hahn HJ, Lee YW, Choe YB, Ahn KJ. Metaanalysis of BRAF mutations and clinicopathologic
characteristics in primary melanoma. J Am Acad Dermatol. 2015;72:1036-46.e2. doi: 10.1016/j.jaad.2015.02.1113.
Lee JH1, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164:776-84. doi: 10.1111/j.1365-2133.2010.10185.x.
Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004;10:1753-7.
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
